Combination therapies to inhibit LCK tyrosine kinase and mTOR signaling in T-cell Acute Lymphoblastic Leukemia. Laukkanen S, Bacquelaine Veloso A, Yan C, Oksa L, et al. Blood 2022 May 11. pii: 485213. doi: 10.1182/blood.2021015106.

Read + Share

Amedeo Smart

Independent Medical Education

Laukkanen S, Bacquelaine Veloso A, Yan C, Oksa L, et al. Combination therapies to inhibit LCK tyrosine kinase and mTOR signaling in T-cell Acute Lymphoblastic Leukemia. Blood 2022 May 11. pii: 485213. doi: 10.1182/blood.2021015106.
PMID: 35544598